These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21209626)

  • 41. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 43. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.
    Li Z; Chi Z; Ang WX; Chen C; Tay JC; Ng YY; Xu X; Wang J; Zhu J; Wang S
    Immunotherapy; 2020 Jul; 12(10):733-748. PubMed ID: 32571133
    [No Abstract]   [Full Text] [Related]  

  • 44. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone marrow transplantation generates T cell-dependent control of myeloma in mice.
    Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR
    J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
    Peinert S; Prince HM; Guru PM; Kershaw MH; Smyth MJ; Trapani JA; Gambell P; Harrison S; Scott AM; Smyth FE; Darcy PK; Tainton K; Neeson P; Ritchie DS; Hönemann D
    Gene Ther; 2010 May; 17(5):678-86. PubMed ID: 20200563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
    Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
    Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells.
    Liu X; Sun M; Yu S; Liu K; Li X; Shi H
    Onco Targets Ther; 2015; 8():3095-104. PubMed ID: 26543378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
    André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
    Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3
    Lee SH; Shin DJ; Kim Y; Kim CJ; Lee JJ; Yoon MS; Uong TNT; Yu D; Jung JY; Cho D; Jung BG; Kim SK; Suh GH
    Front Immunol; 2018; 9():841. PubMed ID: 29755462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
    Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
    Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
    Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
    Front Immunol; 2021; 12():653081. PubMed ID: 33936075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming Target Driven Fratricide for T Cell Therapy.
    Breman E; Demoulin B; Agaugué S; Mauën S; Michaux A; Springuel L; Houssa J; Huberty F; Jacques-Hespel C; Marchand C; Marijsse J; Nguyen T; Ramelot N; Violle B; Daro D; De Waele P; Gilham DE; Steenwinckel V
    Front Immunol; 2018; 9():2940. PubMed ID: 30619300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.
    Hanaoka N; Jabri B; Dai Z; Ciszewski C; Stevens AM; Yee C; Nakakuma H; Spies T; Groh V
    J Immunol; 2010 Nov; 185(10):5732-42. PubMed ID: 20926796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells.
    Massaia M; Attisano C; Peola S; Montacchini L; Omedé P; Corradini P; Ferrero D; Boccadoro M; Bianchi A; Pileri A
    Blood; 1993 Sep; 82(6):1787-97. PubMed ID: 8400233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.